Go Pro
→ 1 Stock to Own by July 31st (From Chaikin Analytics) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.11 -0.01 (-4.35%)
As of 07/31/2026 11:12 AM Eastern
Compare

OBD vs. IXI, APTA, CLBX, RLM, and NSCI

Should you buy Oxford BioDynamics stock or one of its competitors? MarketBeat compares Oxford BioDynamics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford BioDynamics include IXICO (IXI), Aptamer Group (APTA), Cellbxhealth (CLBX), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to IXICO?

IXICO (LON:IXI) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

IXICO has a net margin of -24.98% compared to Oxford BioDynamics' net margin of -825.61%. IXICO's return on equity of -16.18% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-24.98% -16.18% -10.40%
Oxford BioDynamics -825.61%-451.74%-56.23%

In the previous week, IXICO and IXICO both had 1 articles in the media. IXICO's average media sentiment score of 1.70 beat Oxford BioDynamics' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IXICO
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Oxford BioDynamics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

IXICO has higher revenue and earnings than Oxford BioDynamics. IXICO is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£7.28M2.26-£3.58M-£1.95N/A
Oxford BioDynamics£1.20M3.95-£103.52M-£0.20N/A

13.0% of IXICO shares are held by institutional investors. Comparatively, 25.3% of Oxford BioDynamics shares are held by institutional investors. 3.0% of IXICO shares are held by insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

IXICO and Oxford BioDynamics tied by winning 6 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Aptamer Group?

Oxford BioDynamics (LON:OBD) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

25.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by insiders. Comparatively, 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aptamer Group has a net margin of -178.52% compared to Oxford BioDynamics' net margin of -825.61%. Aptamer Group's return on equity of -135.35% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Aptamer Group -178.52%-135.35%-44.96%

In the previous week, Oxford BioDynamics had 1 more articles in the media than Aptamer Group. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Aptamer Group. Oxford BioDynamics' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Aptamer Group Neutral

Aptamer Group has higher revenue and earnings than Oxford BioDynamics. Aptamer Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M3.95-£103.52M-£0.20N/A
Aptamer Group£1.38M11.58-£14.17M-£0.11N/A

Oxford BioDynamics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.902, suggesting that its stock price is 10% less volatile than the broader market.

Summary

Aptamer Group beats Oxford BioDynamics on 8 of the 12 factors compared between the two stocks.

How does Oxford BioDynamics compare to Cellbxhealth?

Oxford BioDynamics (LON:OBD) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Cellbxhealth has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Cellbxhealth's return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Cellbxhealth N/A N/A N/A

In the previous week, Oxford BioDynamics had 1 more articles in the media than Cellbxhealth. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Cellbxhealth. Oxford BioDynamics' average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Cellbxhealth Neutral

25.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cellbxhealth has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M3.95-£103.52M-£0.20N/A
Cellbxhealth£1.15M12.74N/A-£5.51N/A

Summary

Oxford BioDynamics and Cellbxhealth tied by winning 5 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to Realm Therapeutics?

Realm Therapeutics (LON:RLM) and Oxford BioDynamics (LON:OBD) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Realm Therapeutics has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Realm Therapeutics' return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Realm TherapeuticsN/A N/A N/A
Oxford BioDynamics -825.61%-451.74%-56.23%

In the previous week, Oxford BioDynamics had 1 more articles in the media than Realm Therapeutics. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Realm Therapeutics. Realm Therapeutics' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Realm Therapeutics Neutral
Oxford BioDynamics Neutral

25.3% of Oxford BioDynamics shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Realm Therapeutics has higher earnings, but lower revenue than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Realm Therapeutics£501.92K0.00N/A-£17.50N/A
Oxford BioDynamics£1.20M3.95-£103.52M-£0.20N/A

Summary

Oxford BioDynamics beats Realm Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Oxford BioDynamics compare to NetScientific?

NetScientific (LON:NSCI) and Oxford BioDynamics (LON:OBD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

NetScientific has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
Oxford BioDynamics£1.20M3.95-£103.52M-£0.20N/A

NetScientific has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

14.7% of NetScientific shares are held by institutional investors. Comparatively, 25.3% of Oxford BioDynamics shares are held by institutional investors. 42.4% of NetScientific shares are held by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oxford BioDynamics had 1 more articles in the media than NetScientific. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for NetScientific. NetScientific's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Oxford BioDynamics Neutral

NetScientific has a net margin of -182.91% compared to Oxford BioDynamics' net margin of -825.61%. NetScientific's return on equity of -13.70% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Oxford BioDynamics -825.61%-451.74%-56.23%

Summary

NetScientific beats Oxford BioDynamics on 8 of the 11 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£4.93M£3.55B£7.17B£2.79B
Dividend YieldN/A3.78%2.59%6.15%
P/E Ratio-0.557.38282.25368.29
Price / Sales3.951,270.32588.6483,501.30
Price / Cash3.9844.8028.6027.89
Price / Book0.1416.7810.937.04
Net Income-£103.52M-£12.56M£3.50B£5.89B
7 Day PerformanceN/A-1.47%-0.24%6.43%
1 Month PerformanceN/A-8.45%-3.70%0.02%
1 Year Performance-80.94%48.32%61.98%63.72%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.11
-4.3%		N/A-80.9%£4.93M£1.20MN/A45
IXI
IXICO
N/AGBX 8.10
-4.7%		N/A-36.2%£17.74M£7.28MN/A89
APTA
Aptamer Group
N/AGBX 0.50
+8.7%		N/A+29.1%£17.28M£1.38MN/A37
CLBX
Cellbxhealth
N/AGBX 1.33
+3.9%		N/AN/A£15.06M£1.15MN/AN/A
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners
A 50-year dollar arrangement just ended - what it means for you
In 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...
Golden Portfolio | Sponsoredtc pixel